Overexpression of microRNA-30b improves adenovirus-mediated p53 cancer gene therapy for laryngeal carcinoma

International Journal of Molecular Sciences

Volumn 15, Issue 11, 2014, Pages 19729-19740

  Li, Liang ^a,d   Wang, Binquan ^a,b,c  

^a SHANXI MEDICAL UNIVERSITY   (China)

^b The Shanxi Key Laboratory of Otorhinolaryngology Head and Neck Cancer   (China)

^c Key Institute and Laboratory of Otolaryngology affiliated with Shanxi Province   (China)

^d THE SECOND AFFILIATED HOSPITAL OF NANJING MEDICAL UNIVERSITY   (China)

Author keywords

Field cancerization; Laryngeal carcinoma; miR 30b; P53

Indexed keywords

MICRORNA; MICRORNA 30B; PROTEIN MDM2; PROTEIN P53; UNCLASSIFIED DRUG; CARRIER PROTEIN; MIRN30 MICRORNA, HUMAN; MTBP PROTEIN, MOUSE;

ADENOVIRUS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER GENE THERAPY; CLINICAL ARTICLE; DOWN REGULATION; FEMALE; GENE AMPLIFICATION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LARYNX CARCINOMA; LASER CAPTURE MICRODISSECTION; MALE; MOUSE; MTT ASSAY; NICK END LABELING; NONHUMAN; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA ISOLATION; TISSUE PREPARATION; VIRAL GENE THERAPY; WESTERN BLOTTING; ADENOVIRIDAE; ANIMAL; ANTAGONISTS AND INHIBITORS; BAGG ALBINO MOUSE; CARCINOMA; GENE THERAPY; GENE VECTOR; GENETICS; LARYNGEAL NEOPLASMS; METABOLISM; NUDE MOUSE; PATHOLOGY; TUMOR CELL LINE; XENOGRAFT;

ADENOVIRIDAE;

ADENOVIRIDAE; ANIMALS; CARCINOMA; CARRIER PROTEINS; CELL LINE, TUMOR; FEMALE; GENETIC THERAPY; GENETIC VECTORS; HUMANS; LARYNGEAL NEOPLASMS; MICE; MICE, INBRED BALB C; MICE, NUDE; MICRORNAS; TRANSPLANTATION, HETEROLOGOUS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84908322095     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms151119729     Document Type: Article

References (28)

1. Stell, P.M. Survival times in end-stage head and neck cancer. Eur. J. Surg. Oncol. 1989, 15, 407-410.
2. Rudolph, E.; Dyckhoff, G.; Becher, H.; Dietz, A.; Ramroth, H. Effects of tumour stage, comorbidity and therapy on survival of laryngeal cancer patients: A systematic review and a meta-analysis. Eur. Arch. Otorhinolaryngol. 2011, 268, 165-179.
3. Jaiswal, G.; Jaiswal, S.; Kumar, R.; Sharma, A. Field cancerization: Concept and clinical implications in head and neck squamous cell carcinoma. J. Exp. Ther. Oncol. 2013, 10, 209-214.
4. Slaughter, D.P.; Southwick, H.W.; Smejkal, W. Field cancerization in oral stratified squamous epithelium; clinical implications of multicentric origin. Cancer 1953, 6, 963-968.
5. Calin, G.A.; Croce, C.M. MicroRNA-cancer connection: The beginning of a new tale. Cancer Res. 2006, 66, 7390-7394.
6. Nakanishi, H.; Taccioli, C.; Palatini, J.; Fernandez-Cymering, C.; Cui, R.; Kim, T.; Volinia, S.; Croce, C.M. Loss of miR-125b-1 contributes to head and neck cancer development by dysregulating TACSTD2 and MAPK pathway. Oncogene 2014, 33, 702-712.
7. Liu, M.; Wu, H.; Liu, T.; Li, Y.; Wang, F.; Wan, H.; Li, X.; Tang, H. Regulation of the cell cycle gene, BTG2, by miR-21 in human laryngeal carcinoma. Cell Res. 2009, 19, 828-837.
8. Guo, Y.; Fu, W.; Chen, H.; Shang, C.; Zhong, M. miR-24 functions as a tumor suppressor in Hep2 laryngeal carcinoma cells partly through down-regulation of the S100A8 protein. Oncol. Rep. 2012, 27, 1097-1103.
9. Siegel, R.; Naishadham, D.; Jemal, A. Cancer statistics, 2013. CA Cancer J. Clin. 2013, 63, 11-30.
10. Sano, D.; Fooshee, D.R.; Zhao, M.; Andrews, G.A.; Frederick, M.J.; Galer, C.; Milas, Z.L.; Morrow, P.K.; Myers, J.N. Targeted molecular therapy of head and neck squamous cell carcinoma with the tyrosine kinase inhibitor vandetanib in a mouse model. Head Neck 2011, 33, 349-358.
11. Ha, P.K.; Califano, J.A. The molecular biology of mucosal field cancerization of the head and neck. Crit. Rev. Oral Biol. Med. 2003, 14, 363-369.
12. Tabor, M.P.; Brakenhoff, R.H.; van Houten, V.M.; Kummer, J.A.; Snel, M.H.; Snijders, P.J.; Snow, G.B.; Leemans, C.R.; Braakhuis, B.J. Persistence of genetically altered fields in head and neck cancer patients: Biological and clinical implications. Clin. Cancer Res. 2001, 7, 1523-1532.
13. Farazi, T.A.; Spitzer, J.I.; Morozov, P.; Tuschl, T. miRNAs in human cancer. J. Pathol. 2011, 223, 102-115.
14. Sotillo, E.; Thomas-Tikhonenko, A. Shielding the messenger (RNA): MicroRNA-based anticancer therapies. Pharmacol. Ther. 2011, 131, 18-32.
15. Li, W.; Ma, H.; Sun, J. MicroRNA34a/c function as tumor suppressors in Hep2 laryngeal carcinoma cells and may reduce GALNT7 expression. Mol. Med. Rep. 2014, 9, 1293-1298.
16. Le Guillou, S.; Sdassi, N.; Laubier, J.; Passet, B.; Vilotte, M.; Castille, J.; Laloe, D.; Polyte, J.; Bouet, S.; Jaffrezic, F., et al. Overexpression of miR-30b in the developing mouse mammary gland causes a lactation defect and delays involution. PLoS One 2012, 7, e45727.
17. Zhu, E.D.; Li, N.; Li, B.S.; Li, W.; Zhang, W.J.; Mao, X.H.; Guo, G.; Zou, Q.M.; Xiao, B. miR-30b, Down-regulated in gastric cancer, promotes apoptosis and suppresses tumor growth by targeting plasminogen activator inhibitor-1. PLoS One 2014, 9, e106049.
18. Kern, S.E.; Kinzler, K.W.; Bruskin, A.; Jarosz, D.; Friedman, P.; Prives, C.; Vogelstein, B. Identification of p53 as a sequence-specific DNA-binding protein. Science 1991, 252, 1708-1711.
19. Moll, U.M.; Petrenko, O. The MDM2-p53 interaction. Mol. Cancer Res. 2003, 1, 1001-1008.
20. Mandke, P.; Wyatt, N.; Fraser, J.; Bates, B.; Berberich, S.J.; Markey, M.P. MicroRNA-34a modulates MDM4 expression via a target site in the open reading frame. PLoS One 2012, 7, e42034.
21. Zhang, S.; Xu, G.; Liu, C.; Xiao, S.; Sun, Y.; Su, X.; Cai, Y.; Li, D.; Xu, B. Clinical study of recombinant adenovirus-p53 (Adp53) combined with hyperthermia in advanced cancer (a report of 15 cases). Int. J. Hyperth. 2005, 21, 631-636.
22. Kroumpouzos, G.; Eberle, J.; Garbe, C.; Orfanos, C.E. P53 mutation and c-fos overexpression are associated with detection of the antigen VLA-2 in human melanoma cell lines. Pigment Cell Res. 1994, 7, 348-353.
23. Miyashita, T.; Krajewski, S.; Krajewska, M.; Wang, H.G.; Lin, H.K.; Liebermann, D.A.; Hoffman, B.; Reed, J.C. Tumor suppressor p53 is a regulator of bcl-2 and bax gene expression in vitro and in vivo. Oncogene 1994, 9, 1799-1805.
24. Wu, G.S.; Ding, Z. Caspase 9 is required for p53-dependent apoptosis and hemosensitivity in a human ovarian cancer cell line. Oncogene 2002, 21, 1-8.
25. Espina, V.; Wulfkuhle, J.D.; Calvert, V.S.; VanMeter, A.; Zhou, W.; Coukos, G.; Geho, D.H.; Petricoin, E.F., Liotta, L.A. Laser-capture microdissection. Nat. Protoc. 2006, 1, 586-603.
26. Wu, J.; Sun, P.; Zhang, X.; Liu, H.; Jiang, H.; Zhu, W.; Wang, H. Inhibition of GPR40 protects MIN6 β cells from palmitate-induced ER stress and apoptosis. J. Cell. Biochem. 2012, 113, 1152-1158.
27. Wang, T.; Sun, P.; Chen, L.; Huang, Q.; Chen, K.; Jia, Q.; Li, Y.; Wang, H. Cinnamtannin D-1 protects pancreatic β-cells from palmitic acid-induced apoptosis by attenuating oxidative stress. J. Agric. Food Chem. 2014, 62, 5038-5045.
28. Sun, P.; Wang, T.; Zhou, Y.; Liu, H.; Jiang, H.; Zhu, W.; Wang, H. DC260126: A small-molecule antagonist of GPR40 that protects against pancreatic beta-Cells dysfunction in db/db mice. PLoS One 2013, 8, e66744.